Ectopic Pregnancy Global Market Report 2024

The ectopic pregnancy market size has grown strongly in recent years. It will grow from $7.62 billion in 2023 to $8.09 billion in 2024 at a compound annual growth rate (CAGR) of 6.2%. The growth in the historic period can be attributed to increased awareness and early detection, a rise in the incidence of pelvic inflammatory disease, expansion in research and development in women's reproductive health, increased awareness and education about ectopic pregnancies, more fertility treatments, and enhanced maternal healthcare infrastructure.

The ectopic pregnancy market size is expected to see strong growth in the next few years. It will grow to $10.35 billion in 2028 at a compound annual growth rate (CAGR) of 6.3%. The growth in the forecast period can be attributed to the increasing prevalence of gynecological disorders, rising awareness and early detection, growing healthcare expenditure, rising incidence rates, increasing healthcare services, and the growing adoption of minimally invasive surgeries. Major trends during this period include the adoption of advanced diagnostic tools, advancements in minimally invasive surgical procedures, improvements in treatment options, advancements in early diagnostic technologies, and the expansion of telemedicine for remote patient monitoring.

The growth in the use of contraceptive devices is expected to boost the ectopic pregnancy market moving forward. Contraceptive devices are tools that prevent pregnancy by either inhibiting egg fertilization or the implantation of a fertilized egg. This increase in contraceptive device usage is driven by a greater focus on family planning, population management, and the desire to avoid unintended pregnancies. However, the rising use of contraceptive devices, especially intrauterine devices (IUDs), can heighten the risk of ectopic pregnancy if conception occurs. This is because these devices can disrupt the natural movement of the egg through the fallopian tubes, leading to implantation outside the uterus. For example, the Faculty of Sexual and Reproductive Healthcare (FSRH), a UK-based organization, reported that from 2022 to 2023, the utilization of long-acting reversible contraceptives (LARC) increased to 44.1 per 1,000 individuals, up from 41.8 per 1,000 in the previous year, 2021 to 2022. Consequently, the surge in contraceptive device use is propelling the growth of the ectopic pregnancy market.

Major companies in the ectopic pregnancy market are leveraging artificial intelligence (AI) to develop ultrasound systems that enhance diagnostic accuracy and improve patient outcomes. AI-powered ultrasound systems utilize machine learning algorithms to analyze ultrasound images, thereby enhancing the speed and precision of ectopic pregnancy diagnosis. For instance, Samsung Medison, a South Korea-based medical device company, introduced the V8 in September 2021, an AI-enabled ultrasound system featuring BiometryAssist for automated fetal biometry measurements and LaborAssist for determining labor progression by identifying fetal position automatically. These technological advancements significantly enhance ectopic pregnancy detection efficiency and accuracy, potentially reducing complications.

In April 2022, Halozyme Therapeutics Inc., a US-based biotechnology company, acquired Antares Pharma for $960 million. This acquisition bolsters drug delivery technology with Antares' auto-injector systems, enhancing Halozyme's product portfolio and improving patient experiences. Specifically, the advanced auto-injectors used in methotrexate injections for treating ectopic pregnancy offer greater efficiency and user-friendliness, potentially enhancing patient adherence and treatment outcomes. Antares Pharma, a US-based pharmaceutical company, specializes in ectopic pregnancy treatment.

Major companies operating in the ectopic pregnancy market are Pfizer Inc., F. Hoffmann-La Roche Ltd, AbbVie Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, Novartis AG, Fresenius Kabi USA, Eli Lilly and Company, Amgen Inc., Merck KGaA, Teva Pharmaceutical Industries Ltd, Daiichi Sankyo Company Limited, Eisai Co. Ltd., Boehringer Ingelheim International GmbH, Sun Pharmaceutical Industries Limited, Aurobindo Pharma USA, H. Lundbeck A/S, Dr. Reddy's Laboratories, Hikma Pharmaceuticals Plc, Lupin Pharmaceuticals Inc., Zydus Pharmaceuticals, Stason Pharmaceuticals, Actiza Pharmaceutical Private Limited, Zhejiang Davi Pharmaceutical Co., Ltd.

North America was the largest region in the ectopic pregnancy market in 2023. The regions covered in the ectopic pregnancy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the ectopic pregnancy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Ectopic pregnancy is a medical condition where a fertilized egg implants and develops outside the uterus, typically in the fallopian tubes. This poses significant risks if not identified and managed promptly, as the embryo cannot develop normally outside the uterus and can cause life-threatening complications such as rupture and internal bleeding if left untreated.

The main types of ectopic pregnancy are tubal ectopic pregnancy, non-tubal ectopic pregnancy, heterotopic ectopic pregnancy, and others. A tubal ectopic pregnancy occurs when a fertilized egg implants and begins to grow within the fallopian tubes, which transfer eggs from the ovaries to the uterus. Treatments, such as folic acid analogues and corticosteroids, are distributed through various channels, including retail, online, and hospital pharmacies, and cater to hospitals, clinics, fertility centers, and other end-users.

The ectopic pregnancy market research report is one of a series of new reports that provides ectopic pregnancy market statistics, including the ectopic pregnancy industry global market size, regional shares, competitors with ectopic pregnancy market share, detailed ectopic pregnancy market segments, market trends, and opportunities, and any further data you may need to thrive in the ectopic pregnancy industry. These ectopic pregnancy market research reports deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The ectopic pregnancy market consists of revenues earned by entities by providing services such as diagnostic services, emergency medical services, surgical services, and pharmacological treatment services. The market value includes the value of related goods sold by the service provider or included within the service offering. The ectopic pregnancy market also includes sales of ultrasound machines, hormone level monitoring kits, and medications such as methotrexate for medical management. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.